CN102137869B - Fn14/TRAIL融合蛋白 - Google Patents

Fn14/TRAIL融合蛋白 Download PDF

Info

Publication number
CN102137869B
CN102137869B CN200980133865.2A CN200980133865A CN102137869B CN 102137869 B CN102137869 B CN 102137869B CN 200980133865 A CN200980133865 A CN 200980133865A CN 102137869 B CN102137869 B CN 102137869B
Authority
CN
China
Prior art keywords
trail
cells
fusion protein
cancer
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980133865.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102137869A (zh
Inventor
M·拉兹马拉
M·L·泰科辛斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of CN102137869A publication Critical patent/CN102137869A/zh
Application granted granted Critical
Publication of CN102137869B publication Critical patent/CN102137869B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200980133865.2A 2008-06-30 2009-06-30 Fn14/TRAIL融合蛋白 Active CN102137869B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13353208P 2008-06-30 2008-06-30
US61/133,532 2008-06-30
PCT/US2009/003886 WO2010005519A1 (en) 2008-06-30 2009-06-30 Fn14/trail fusion proteins

Publications (2)

Publication Number Publication Date
CN102137869A CN102137869A (zh) 2011-07-27
CN102137869B true CN102137869B (zh) 2018-07-06

Family

ID=41278748

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980133865.2A Active CN102137869B (zh) 2008-06-30 2009-06-30 Fn14/TRAIL融合蛋白

Country Status (9)

Country Link
US (3) US8039437B2 (enExample)
EP (2) EP2297198B1 (enExample)
JP (1) JP5475766B2 (enExample)
CN (1) CN102137869B (enExample)
AU (1) AU2009269141B2 (enExample)
CA (1) CA2729351C (enExample)
IL (1) IL210175A0 (enExample)
SG (1) SG191698A1 (enExample)
WO (1) WO2010005519A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2525822B1 (en) 2010-01-20 2017-05-10 Merck Sharp & Dohme Corp. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
EP2525813B1 (en) 2010-01-20 2017-01-04 Merck Sharp & Dohme Corp. Anti-ilt5 antibodies and ilt5-binding antibody fragments
PL391627A1 (pl) * 2010-06-25 2012-01-02 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
CN103153332A (zh) 2010-09-28 2013-06-12 卡尔医疗有限公司 用于治疗血液恶性肿瘤的组合物和方法
PL219845B1 (pl) * 2011-01-05 2015-07-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
CN102206281B (zh) * 2011-03-28 2014-04-09 中国人民解放军第三军医大学第一附属医院 融合蛋白tetph、表达载体及其构建方法
WO2012145568A1 (en) 2011-04-21 2012-10-26 Albert Einstein College Of Medicine Of Yeshiva University Antibodies to human b7x for treatment of metastatic cancer
PL397167A1 (pl) * 2011-11-28 2013-06-10 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
WO2014121093A1 (en) * 2013-01-31 2014-08-07 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
US10533054B2 (en) 2013-01-31 2020-01-14 Thomas Jefferson University Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system
WO2014121085A1 (en) * 2013-01-31 2014-08-07 Thomas Jefferson University Pd-l1 and pd-l2-based fusion proteins and uses thereof
US9797882B2 (en) 2013-07-09 2017-10-24 The Translational Genomics Research Institute Method of screening for a compound for inhibitory activity of FN14-tweak interaction
US9238034B2 (en) 2013-07-09 2016-01-19 The Translational Genomics Research Institute FN14 antagonists and therapeutic uses thereof
US11111284B2 (en) 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
WO2016139668A2 (en) * 2015-03-03 2016-09-09 Kahr Medical (2005) Ltd Dual signaling protein (dsp) fusion proteins, and methods of using thereof for treating diseases
IL316210A (en) 2015-10-01 2024-12-01 Heat Biologics Inc Compounds and methods for connecting type 1 and 2 extracellular complexes as heterologous chimeric proteins
DK3565579T3 (da) 2017-01-05 2023-09-04 Kahr Medical Ltd Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
HRP20220230T1 (hr) 2017-01-05 2022-04-29 Kahr Medical Ltd. Sirp1 alfa-41bbl fuzijski protein i metoda njegove upotrebe
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
WO2018127916A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-cd70 fusion protein and methods of use thereof
EP3585409A4 (en) 2017-02-27 2020-12-02 Shattuck Labs, Inc. CHEMERICAL PROTEINS BASED ON CSF1R
JP7128195B2 (ja) 2017-02-27 2022-08-30 シャタック ラボ，インコーポレイテッド 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法
EP3585410B9 (en) 2017-02-27 2023-10-04 Shattuck Labs, Inc. Vsig8-based chimeric proteins
WO2019129644A1 (en) * 2017-12-28 2019-07-04 Julius-Maximilians-Universität Würzburg TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FcγR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCγR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA)
SG11202013167UA (en) 2018-07-11 2021-01-28 Kahr Medical Ltd SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
CN112543767B (zh) 2018-07-11 2024-05-31 卡尔医学有限公司 Pd1-4-1bbl变体融合蛋白及其使用方法
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
JP2022541742A (ja) 2019-07-11 2022-09-27 カール メディカル リミテッド ヘテロダイマーおよびその使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045730A2 (en) * 1999-12-20 2001-06-28 Immunex Corporation Tweak receptor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
US7378089B2 (en) 2001-10-02 2008-05-27 The Board Of Trustees Of The Leland Stanford Junior University Gene therapy for the prevention of autoimmune disease
SI1997512T1 (sl) * 2002-04-09 2014-03-31 Biogen Idec Ma Inc. Postopki za zdravljenje stanj, povezanih s TWEAK-om
ATE505484T1 (de) * 2002-10-29 2011-04-15 Anaphore Inc Trimer-proteine zur trimer-zytokine
AU2004259355B2 (en) * 2003-07-24 2011-02-03 Amgen Inc. Compositions and methods relating to multimeric and oligomeric soluble fragments of the tweak receptor
US7285522B2 (en) 2004-08-25 2007-10-23 The Clorox Company Bleaching with improved whitening

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045730A2 (en) * 1999-12-20 2001-06-28 Immunex Corporation Tweak receptor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TNF相关凋亡诱导配基抑制肿瘤细胞的机制探索;杨瑜等;《武警医学》;20030731;第14卷(第7期);第419-421页 *
TRAIL (Apo2 Ligand)and TWEAK (Apo3 Ligand) Mediate CD4+ T Cell Killing of Antigen-presenting Macrophages;Kaplan.MJ;《The journal of Immunology》;20000315;第164卷(第6期);第2897-2904页 *

Also Published As

Publication number Publication date
CA2729351C (en) 2017-01-24
US8329657B2 (en) 2012-12-11
EP2297198B1 (en) 2014-12-17
JP5475766B2 (ja) 2014-04-16
IL210175A0 (en) 2011-03-31
JP2011526891A (ja) 2011-10-20
US20130065815A1 (en) 2013-03-14
US20100048478A1 (en) 2010-02-25
AU2009269141A1 (en) 2010-01-14
EP2297198A1 (en) 2011-03-23
SG191698A1 (en) 2013-07-31
AU2009269141B2 (en) 2013-04-04
US8039437B2 (en) 2011-10-18
EP2460827A1 (en) 2012-06-06
CA2729351A1 (en) 2010-01-14
US20120028909A1 (en) 2012-02-02
WO2010005519A1 (en) 2010-01-14
CN102137869A (zh) 2011-07-27

Similar Documents

Publication Publication Date Title
CN102137869B (zh) Fn14/TRAIL融合蛋白
Kucka et al. Receptor oligomerization and its relevance for signaling by receptors of the tumor necrosis factor receptor superfamily
US10364279B2 (en) PD-L1 and PD-L2-based fusion proteins and uses thereof
Thompson et al. BAFF binds to the tumor necrosis factor receptor–like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population
US9221895B2 (en) OX40/TRAIL fusion proteins
NO331683B1 (no) Anvendelse av et spesifikt polypeptid eller antistoff mot dette for fremstilling av et medikament til behandling av tumorceller som uttrykker APRIL.
SK288603B6 (sk) Polypeptid a protilátka viažuca sa na polypeptid
US20220056102A1 (en) Multi-functional fusion proteins and uses thereof
US20180169183A1 (en) Dual signaling protein (dsp) fusion proteins, and methods of using thereof for treating diseases
AU8175898A (en) Protein that binds trail
US9920119B2 (en) Chimeric molecule involving oligomerized FasL extracellular domain

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant